Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.59 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268053 | 0.89 | HTR1A (0.73) | HTR1ADRD2MGLLLMNAABCB1 | |
| SCHEMBL5658392 | 0.87 | TP53 (0.47) | HTR1ADRD2LMNAABCB1L3MBTL1 | |
| SCHEMBL7620729 | 0.82 | HTR1A (0.63) | HTR1ADRD2MGLLLMNAABCB1 | |
| SCHEMBL5657721 | 0.81 | PPARD (0.47) | LMNAGAAL3MBTL1MAPTALDH1A1 | |
| SCHEMBL5250481 | 0.80 | HTR1A (0.53) | HTR1ADRD2LMNAABCB1L3MBTL1 | |
| SCHEMBL11040584 | 0.80 | CA12 (0.58) | KDM4E | |
| SCHEMBL31561714 | 0.80 | HTR1A (0.69) | HTR1ADRD2MGLLLMNAABCB1 | |
| SCHEMBL3159332 | 0.80 | HTR1A (0.69) | HTR1ADRD2MGLLLMNAABCB1 | |
| SCHEMBL5660413 | 0.79 | HTR1A (0.59) | HTR1ADRD2MGLLABCB1PTGER1 | |
| SCHEMBL8808610 | 0.79 | MGLL (0.67) | HTR1ADRD2MGLLLMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100384836-C | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2008-04-30 | — | — | CN | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| CN-1426405-A | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-06-25 | — | — | CN | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 79/4885DRD2 402/4885MGLL 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.